Recently, some data have indicated that irinotecan may worsen hepatic oxidative stress by inducing the formation of ROS and lipid peroxides while simultaneously lowering GSH, superoxide dismutase (SOD), and catalase (CAT) in cancer cells [152]. The gene discussed is CAT; the disease is cancer.